|
|
|
29.05.26 - 22:18
|
Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 16,950 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on May 28, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
29.05.26 - 22:06
|
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options and 19,200 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 28, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
29.05.26 - 22:06
|
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropat (GlobeNewswire EN)
|
|
|
SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss results from the ongoing Phase 1 healthy volunteer study of JADE101. The data are expected to define the dosing strategy and further characterize JADE101's clinical profile as a potentially differentiated, disease-modifying anti–A Proliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN)....
|
|
|
|
|
29.05.26 - 22:03
|
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
|
|
|
THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m. ET on Thursday, June 4, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, Narimon Honarpour, senior vice president......
|
|
|
|
|
29.05.26 - 21:51
|
"Closing The Nuclear Fuel Cycle" - Newcleo′s $780M War Chest And Oklo Partnership Fuel $2.4B SPAC Debut (ZeroHedge)
|
|
|
"Closing The Nuclear Fuel Cycle" - Newcleo's $780M War Chest And Oklo Partnership Fuel $2.4B SPAC Debut
It's open season in the nuclear industry for going public, and this week's episode features newcleo, a European lead-cooled reactor developer.
The Paris-based developer of lead-cooled fast reactors (LFRs) and closed-cycle MOX fuel announced it will merge with NewHold Investment Corp III (ticker NHIC) in a deal valuing the company at roughly $2.4 billion.
A $220 million oversubscribed PIPE at $10 per share plus up to $209 million from the SPAC trust should deliver as much as $429 million in gross proceeds before redemptions and fees. The combined entity expects to list on Nasdaq under ticker NWCL in the second half of 2026.
Hopefully their transition to public markets doesn't follow the same path as microreactor developer Hadron Energy…
Founded by Stefano Buono (the man who took Advanced Accelerator Applications public on Nasdaq in 2015 and sold it to Novartis for $3.9 bil...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
